PRODUCTION BASE

PRODUCTION BASE

Jilin Bio-Omega


Jilin Bio-Omega Biotechnology Co., Ltd. was established in August 2020 and has since built a production base with an annual capacity of 300 tons of NMN. Currently, the technical upgrade for co-line production of glutathione has been completed.

 

Introduction to Nicotinamide Mononucleotide (NMN)

The company is among the earliest in China to engage in the R&D and production of nicotinamide mononucleotide products, with NMN purity now reaching 99.92%. By establishing a dedicated production line in Jilin Province, the company has standardized its manufacturing processes and rapidly expanded its production capacity. Currently, Jilin Bio-Omega has built an annual NMN production capacity of 300 metric tons, making it one of the largest producers in China.

The company employs a bioenzyme–ribose catalysis process, which, to date, represents the most cost-effective production route. Following the April 2020 FDA clearance of NMN products as non-toxic and free of adverse effects, large-scale domestic production of the product commenced in June 2020.

It is foreseeable that, as production costs decline, applications expand into an increasing number of fields, and public awareness and acceptance grow, nicotinamide mononucleotide (NMN) will have the opportunity to become as ubiquitous in households as vitamins.


Image Name

Return to list